Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) [Seeking Alpha]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Seeking Alpha
Play 8min Summary Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2 schizophrenia data, though dose inconsistencies raised questions about efficacy. The stock's recent decline is an overreaction, presenting a buying opportunity given its CNS pipeline and Ingrezza's ongoing growth. ktsimage Neurocrine: Underperforming the Market, But Poised for a CNS Breakthrough Neurocrine Biosciences NASDAQ: NBIX ) was one of the first biotechnology companies to pique my interest in 2017, following the FDA's landmark approval of Ingrezza for tardive dyskinesia. Since November This article was written by Stephen Ayers 7.35K Follower s Follow I'm a biotech and healthcare investment analyst with several years of clinical experience and a Master of Business Administration. I've had the privilege of sharing my analyses on Seeking
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at BMO Capital Markets from $128.00 to $114.00. They now have a "market perform" rating on the stock.MarketBeat
- Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.MarketBeat
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsPR Newswire
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Royal Bank of Canada from $136.00 to $133.00. They now have a "sector perform" rating on the stock.MarketBeat
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 10/17/24 - Form SC
- 10/11/24 - Form 8-K
- 10/7/24 - Form 4
- NBIX's page on the SEC website